Loading
A phase 1/2 trial of SHR-A2102, Adebrelimab and Disitamab vedotin in advanced solid tumours, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06417554 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 80 participants planned, started 2024-05-27 and due to reach its primary completion in 2031-12-31. Interventions recorded: SHR-A2102, SHR-A2102 ; Adebrelimab injection and SHR-A2102 + Disitamab Vedotin For Injection.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.